Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMENOS 2 trial of trastuzumab emtansine for advanced HER2-positive extramammary Paget's disease
jRCT2031210436Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in extramammary Paget disease (EMPD), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Objective response rate. Started May 2022; status: active, not recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on jRCT2031210436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210436.